212 related articles for article (PubMed ID: 35671049)
1. Potential Therapeutic Role of Bone Morphogenic Protein 7 (BMP7) in the Pathogenesis of Graves' Orbitopathy.
Kim BY; Choi SH; Kim JY; Ko J; Yook JI; Kim HS; Lee EJ; Kikkawa DO; Yoon JS
Invest Ophthalmol Vis Sci; 2022 Jun; 63(6):7. PubMed ID: 35671049
[TBL] [Abstract][Full Text] [Related]
2. Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves' Orbitopathy.
Ko J; Kim YJ; Choi SH; Lee CS; Yoon JS
Thyroid; 2023 Dec; 33(12):1465-1475. PubMed ID: 37800725
[No Abstract] [Full Text] [Related]
3. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
4. Chemokine Expression during Adipogenesis and Inflammation in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee CE; Choi SH; Yoon JS
Korean J Ophthalmol; 2020 Jun; 34(3):192-202. PubMed ID: 32495527
[TBL] [Abstract][Full Text] [Related]
5. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
6. Sphingosine-1-Phosphate Mediates Fibrosis in Orbital Fibroblasts in Graves' Orbitopathy.
Ko J; Chae MK; Lee JH; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2544-2553. PubMed ID: 28492873
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves' orbitopathy.
Jang SY; Park SJ; Chae MK; Lee JH; Lee EJ; Yoon JS
Br J Ophthalmol; 2018 Mar; 102(3):407-414. PubMed ID: 29101123
[TBL] [Abstract][Full Text] [Related]
8. Glycogen Synthase Kinase-3β Mediates Proinflammatory Cytokine Secretion and Adipogenesis in Orbital Fibroblasts from Patients with Graves' Orbitopathy.
Lee JS; Chae MK; Kikkawa DO; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):51. PubMed ID: 32735324
[TBL] [Abstract][Full Text] [Related]
9. The Role of Adipsin, Complement Factor D, in the Pathogenesis of Graves' Orbitopathy.
Byeon HJ; Chae MK; Ko J; Lee EJ; Kikkawa DO; Jang SY; Yoon JS
Invest Ophthalmol Vis Sci; 2023 Aug; 64(11):13. PubMed ID: 37555734
[TBL] [Abstract][Full Text] [Related]
10. Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves' Ophthalmopathy by Targeting Orbital Fibroblasts.
Yang S; Wang X; Xiao W; Xu Z; Ye H; Sha X; Yang H
Front Endocrinol (Lausanne); 2022; 13():891922. PubMed ID: 35663306
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram Exerts Antiadipogenic, Anti-Inflammatory, and Antifibrotic Therapeutic Effects in an
Wang X; Yang S; Ye H; Chen J; Shi L; Feng L; Wang X; Zhang T; Chen R; Xiao W; Yang H
Thyroid; 2022 Mar; 32(3):294-305. PubMed ID: 34605662
[No Abstract] [Full Text] [Related]
12. Therapeutic Potential of Targeting Periostin in the Treatment of Graves' Orbitopathy.
Jang SY; Kim J; Park JT; Liu CY; Korn BS; Kikkawa DO; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2022; 13():900791. PubMed ID: 35707463
[TBL] [Abstract][Full Text] [Related]
13. Phospholipase C-γ as a Potential Therapeutic Target for Graves' Orbitopathy.
Roh TH; Chae MK; Ko JS; Kikkawa DO; Jang SY; Yoon JS
Endocrinol Metab (Seoul); 2023 Dec; 38(6):739-749. PubMed ID: 37989267
[TBL] [Abstract][Full Text] [Related]
14. Association of fibroblast growth factor 10 with the fibrotic and inflammatory pathogenesis of Graves' orbitopathy.
Jang SY; Choi SH; Kikkawa D; Lee EJ; Yoon JS
PLoS One; 2021; 16(8):e0255344. PubMed ID: 34383782
[TBL] [Abstract][Full Text] [Related]
15. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.
van Steensel L; Paridaens D; Dingjan GM; van Daele PL; van Hagen PM; Kuijpers RW; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1002-7. PubMed ID: 19797221
[TBL] [Abstract][Full Text] [Related]
17. M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves' Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor.
Lu Y; Wang Y; Wang Y; Wu Y; Huang Y; Liu X; Zhang S; Zhong S; Li Y; Li B; Sun J; Fang S; Zhou H
Thyroid; 2023 Mar; 33(3):338-350. PubMed ID: 36617890
[No Abstract] [Full Text] [Related]
18. Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.
Rhiu S; Chae MK; Lee EJ; Lee JB; Yoon JS
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):5900-10. PubMed ID: 25159204
[TBL] [Abstract][Full Text] [Related]
19. Essential role of connective tissue growth factor (CTGF) in transforming growth factor-β1 (TGF-β1)-induced myofibroblast transdifferentiation from Graves' orbital fibroblasts.
Tsai CC; Wu SB; Kau HC; Wei YH
Sci Rep; 2018 May; 8(1):7276. PubMed ID: 29739987
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
